Aptevo Therapeutics Inc. (APVO): Operating Cash Flow
-$25.59M
Year ended 2025-12-31
-$25.34M
Trailing 12 months to 2026-06-30
| Period ended | Operating Cash Flow | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$25.59M | n/m | 2026-03-26, From 2025-01-01 |
| 2024-12-31 | -$23.79M | n/m | 2026-03-26, From 2024-01-01 |
| 2023-12-31 | -$11.73M | n/m | 2025-02-14, From 2023-01-01 |
| 2022-12-31 | -$21.02M | n/m | 2024-03-05, From 2022-01-01 |
| 2021-12-31 | -$21.68M | n/m | 2023-03-30, From 2021-01-01 |
| 2020-12-31 | -$29.32M | n/m | 2022-03-24, From 2020-01-01 |
| 2019-12-31 | -$42.38M | n/m | 2021-03-31, From 2019-01-01 |
| 2018-12-31 | -$51.42M | n/m | 2020-03-25, From 2018-01-01 |
| 2017-12-31 | -$41.57M | n/m | 2019-03-18, From 2017-01-01 |
| 2016-12-31 | -$36.86M | n/m | 2018-03-13, From 2016-01-01 |
| 2015-12-31 | -$48.76M | n/a | 2017-03-31, From 2015-01-01 |
Operating Cash Flow at similar companies
| Company | Year ended | Operating Cash Flow | Change YoY |
|---|---|---|---|
| Aptevo Therapeutics Inc. (APVO) | 2025-12-31 | -$25.59M | n/m |
| TuHURA Biosciences, Inc. (HURA) | 2025-12-31 | -$27.63M | n/m |
| Skye Bioscience, Inc. (SKYE) | 2025-12-31 | -$43.06M | n/m |
| BeyondSpring Inc. (BYSI) | 2025-12-31 | -$19.77M | n/m |
| Biofrontera Inc. (BFRI) | 2025-12-31 | -$13.36M | n/m |
| Elicio Therapeutics, Inc. (ELTX) | 2025-12-31 | -$36.95M | n/m |
| Neuphoria Therapeutics Inc. (NEUP) | 2026-06-30 | -$12.35M | n/m |
| CASI Pharmaceuticals, Inc. (CASIF) | 2025-12-31 | -$20.75M | n/m |
| Onconetix, Inc. (ONCO) | 2025-12-31 | -$9.68M | n/m |
Compare APVO, HURA, SKYE, BYSI side by side · Screen every company in Pharmaceutical Preparations ↗